OpenScience.ink

1 week ago • Endocrinology and metabolism clinics of North America

How GLP-1 Receptor Agonists May Affect Contraception, Fertility, and PregnancyGLP-1 Receptor Agonists and Reproductive Health: Implications for Contraception, Fertility, and Pregnancy.

🎖️ Top 10% JournalArticle

1 week ago • The American journal of medicine

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Lung and Digestive Problems After Anesthesia in a Large International StudyThe Impact of Glucagon-Like Peptide-1 Receptor Agonists on Post-Anesthetic Pulmonary and Gastrointestinal Adverse Events: A Target Trial Emulation Using Multinational Database.

📖 Top 20% JournalArticle

1 week ago • Advances in anesthesia

Glucagon-Like Peptide-1 Receptor Agonists: Updated Information on Surgery-Related Effects and GuidelinesAn Updated Review of Glucagon-Like Peptide-1 Receptor Agonists: Perioperative Implications, Guidance Statements, and Current Literature.

📖 Top 50% JournalArticle

1 week ago • The spine journal : official journal of the North American Spine Society

Recovery after Neck Spine Surgery in Type 2 Diabetes Patients Using Diabetes Drugs versus Weight-Loss SurgeryOutcomes after Posterior Cervical Spine Surgery: A Matched Cohort Analysis and Comparison of GLP-1 Receptor Agonist Use and Bariatric Surgery in Patients with Type 2 Diabetes.

🥉 Top 5% JournalArticle

1 week ago • International journal of pharmaceutics

Dissolving microneedles for skin delivery of semaglutide to reduce obesity in ratsPoly(vinyl alcohol) dissolving microneedles for transdermal semaglutide delivery and anti-obesity therapy in rats.

📖 Top 20% JournalArticle

1 week ago • Reviews in endocrine & metabolic disorders

GIP signaling in belly and under-skin fat: possible links to obesity and metabolic diseaseGlucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search.

🥉 Top 5% JournalArticle

1 week ago • Molecular pharmaceutics

A Modified GLP-1R Activator Improves Blood Sugar Control in Tumor-Bearing Rats Without Worsening Appetite Loss or Weight LossA Dicyanocobinamide Conjugate of the GLP-1R Agonist Exendin-4 Improves Glucose Homeostasis in Tumor-Bearing Rats without Exacerbating Anorexia and Weight Loss.

📖 Top 20% JournalArticle

1 week ago • Advances in anesthesia

Managing Blood Sugar Medicines Around SurgeryPerioperative Management of Antihyperglycemic Medications.

📖 Top 50% JournalArticle

1 week ago • The New England journal of medicine

Weekly Retatrutide Treatment for Obstructive Sleep ApneaRetatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.

🏆 Top 0.1% JournalArticle

2 weeks ago • Omics : a journal of integrative biology

Comparing Oral and Injectable Incretin-Based Weight Loss Treatments: A Combined Data Analysis of Orforglipron, Semaglutide, and TirzepatideOral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide.

📖 Top 50% JournalArticle

2 weeks ago • BMJ open

📖 Top 20% JournalArticle

2 weeks ago • Cardiology in review

Tirzepatide’s effects on obstructive sleep apnea, heart and metabolism health, and what this means for heart careTirzepatide for Obstructive Sleep Apnea: Trial Evidence, Cardiometabolic Effects, and Implications for Cardiovascular Practice.

📖 Top 50% JournalArticle

2 weeks ago • Diabetology & metabolic syndrome

Effectiveness and safety of mazdutide compared to dulaglutide in adults with type 2 diabetesEfficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

📖 Top 20% JournalArticle

2 weeks ago • Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Use and effects of diabetes drugs on people being evaluated for kidney transplant in British ColumbiaPrescribing patterns and impact of glucagon-like peptide-1 receptor agonists in a kidney transplant evaluation cohort in British Columbia, Canada A single-center experience.

📖 Top 30% JournalArticle

2 weeks ago • Revista medica de Chile

Effectiveness of Weekly Semaglutide (0.5 or 1 mg) in Chilean Adults with Type 2 DiabetesEffectiveness of Weekly Semaglutide Treatment (0.5 or 1 mg) in Chilean Patients with Type 2 Diabetes Mellitus.

Clinical Trial, Phase IV

2 weeks ago • American journal of epidemiology

Different treatment responses to GLP-1 receptor drugs in people with type 2 diabetesExploring heterogeneous treatment effects for GLP-1 receptor agonists in patients with type 2 diabetes.

🥉 Top 5% JournalArticle

2 weeks ago • Obesity pillars

Factors Influencing Different Responses to GLP-1 Drugs for Personalized Obesity TreatmentDeterminants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity.

📖 Top 20% JournalArticle

2 weeks ago • Cell reports. Medicine

Gut hormones reduce T cell-caused damage in the intestineGut-derived glucagon-like peptides attenuate T cell-induced intestinal injury.

🥈 Top 2% JournalArticle

2 weeks ago • Clinics and research in hepatology and gastroenterology

How Different Doses of Incretin and Multi-Target Drugs Affect Weight LossDose-Response Profiles in Incretin and Multi-Agonist Obesity Pharmacotherapy.

📖 Top 30% JournalArticle

2 weeks ago • Epilepsia

How GLP-1 receptor drugs may change seizure risk depending on the situationBeyond neuroprotection: Context-dependent effects of GLP-1 receptor agonists on seizure susceptibility.

Article

2 weeks ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

How GLP-1 Medicines Affect Eating Habits, Hunger, and Food Intake in Overweight and Obese AdultsInfluence of GLP-1-Based Pharmacotherapies on Eating Behavior, Appetite, and Energy Intake in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.

Article

2 weeks ago • Frontiers in endocrinology

Safety, timing, lasting effects, and body changes of weight-loss drugs during cosmetic surgeryGlucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition.

🎖️ Top 10% JournalArticle

2 weeks ago • Kidney international

Safety of semaglutide in people with different levels of chronic kidney disease in the FLOW trialSafety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial.

🥈 Top 2% JournalArticle

2 weeks ago • Frontiers in endocrinology

How Gut Hormones Affect Bone Health: Molecular Details and Medical ImportanceThe incretin-bone axis: molecular mechanisms and clinical implications.

🎖️ Top 10% JournalArticle

2 weeks ago • Journal of vitreoretinal diseases

Glucagon-Like Peptide-1 Receptor Agonists and Their Link to Risk of Blocked Blood Vessels in the RetinaThe Impact of Glucagon-Like Peptide-1 Receptor Agonists on Risk of Retinal Vascular Occlusions.

📖 Top 50% JournalArticle

2 weeks ago • Diabetic medicine : a journal of the British Diabetic Association

Metabolic and kidney outcomes in people with chronic kidney disease, type 2 diabetes, and obesity taking tirzepatide in everyday careReal-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide.

Article

2 weeks ago • Diabetes, obesity & metabolism

How Starting Semaglutide in Real Life in the US Affects Early Treatment Stopping and Staying on It for One YearReal-World Semaglutide Initiation Behaviours in the United States: Impact on Early Treatment Discontinuation and on 1-Year Persistence.

Article

2 weeks ago • Signal transduction and targeted therapy

Kidney-protective effects of polyethylene glycol-loxenatide in people with type 2 diabetesReal-world renoprotective effects of polyethylene glycol-loxenatide in type 2 diabetes: a multicenter, ambispective cohort study.

🥇 Top 1% JournalMulticenter Study

2 weeks ago • Neurogastroenterology and motility

Gut Symptoms and Movement Changes Linked to GLP-1 Receptor AgonistsGastrointestinal Symptom Events and Motility Alterations Associated With GLP-1 Receptor Agonists.

Article

2 weeks ago • Journal of controlled release : official journal of the Controlled Release Society

Comparing how different enhancers affect intestinal delivery of semaglutideMechanistic benchmarking of SNAC, DDM, and LLC reveals enhancer-dependent pathways for intestinal semaglutide delivery.

Article

← prevpage 8 of 16next →

Latest GLP-1 Therapies Research Papers